Search

Long-acting amylin analog for satiety and gastric emptying control. Pairs with GLP-1 peptides for comprehensive appetite support.

Long-acting GLP-1 analog for appetite regulation and sustained metabolic support. A cornerstone in body-composition and weight-management programs.

FDA logged roughly 3,900 public comments by the July 30, 2026 deadline on whether GLP-1 bulk substances belong on the 503B bulks list—one of the agency's busiest compounding dockets ever.

Eli Lilly's July 2026 TRIUMPH Phase 3 topline showed retatrutide produced up to 28.7% mean weight loss at 68 weeks in obesity patients without diabetes, sending ripples through the peptide supply chain.

Researchers reported in June 2026 that (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone ester co-administration attenuated lean-mass loss in semaglutide-treated rats without blocking fat reduction.

ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.

Product Type：Weight Management PeptideCOA Specification: 5mg per vialShort Introduction:Semaglutide is a popular peptide for weight management. It suppresses appetite, optimizes metabolism and controls blood sugar, supporting sustainable fat loss and body shaping. It is highly recognized for its st